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ABSTRACT 
Lipids in the nervous system are represented by cholesterol and phospholipids as constituents of 
cell membranes and, in particular, of myelin. Therefore, lipids are finely regulated to guarantee 
physiological functions. In the central nervous system, cholesterol is locally synthesized due to the 
presence of the blood brain barrier. In the peripheral nervous system cholesterol is either up-
taken by lipoproteins and/or produced by de novo biosynthesis. Defects in lipid homeostasis in 
these tissues lead to structural and functional changes that often result in different pathological 
conditions depending on the affected pathways (i.e. cholesterol biosynthesis, cholesterol efflux, 
fatty acid biosynthesis etc.). Alterations in cholesterol metabolism in the central nervous system 
are linked to several disorders such as Alzheimer’s disease, Huntington disease, Parkinson disease, 
Multiple Sclerosis, Smith-Lemli-Opitz syndrome, Niemann-Pick type C disease, and glioblastoma. In 
the peripheral nervous system changes in lipid metabolism are associated with the development 
of peripheral neuropathy that may be caused by metabolic disorders, injuries, therapeutics and 
autoimmune diseases. Transcription factors, such as the Liver X receptors (LXRs), regulate both 
cholesterol and fatty acid metabolism in several tissues including the nervous system. In the last 
few years several studies elucidated the biology of LXRs in nervous system due to the availability 
of knock-out mice and the development of synthetic ligands.  
Here, we review a survey of the literature focused on central and peripheral nervous system and 
in physiological and pathological settings with particular attention on the roles played by LXRs in 
both districts. 
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INTRODUCTION 
Liver X Receptors (LXRs) are members of the nuclear receptors superfamily. LXRs have the 
classical structure of a nuclear receptor: a DNA binding domain, a ligand binding domain and a 
ligand independent activation function 2 (AF2) that, through the recruitment of coactivators and 
corepressors, regulates the activity of the receptor.  
More than ten years ago these proteins were discovered, cloned and termed “orphan 
nuclear receptors” (1). Today, since the physiological ligands are known, they are classified as 
“adopted orphans”. 
Two different isoforms, LXR (NR1H3) and LXR (NR1H2) are known. LXR is 
predominantly expressed in the liver and at lower levels also in the intestine, macrophages, 
adipose tissue, lungs, kidneys and the adrenal gland, while LXR is broadly expressed (2) including 
neurons, microglia, astrocytes (3) oligodendrocytes (4), and Schwann cells (5). 
LXRs are ligand activated transcription factors that form an obligate heterodimers with the 
retinoic X receptor (RXR). The LXR/RXR complex, activated by ligands, binds a specific sequence, 
called LXR responsive element (LXRE) in the promoter of the target genes modulating their 
expressions. Usually the DNA sequence recognized by LXRs is a direct repeat of the core 
G/AGGTCA separated by four nucleotides DR-4 (1). However, it has been reported that LXR can 
also bind an inverted repeat (IR) sequence without spacing nucleotides (IR0) (6). 
LXRs natural ligands are represented by oxysterols, an oxidized form of cholesterol 
produced from the cells as intermediates in steroid hormones or bile acids biosynthesis (7). 
Accordingly with the nature of the physiological ligands, LXRs play an important role in cholesterol, 
and lipid metabolism.  
The role of LXRs as an intracellular cholesterol sensor is primarily due to the activation of 
key genes in cholesterol efflux such as the ATP binding cassette (ABC) family and in particular 
ABCA1, ABCG1, ABCG5 and ABCG8, apolipoprotein E (ApoE) and cholesterol ester transfer protein 
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(CETP) (8). This activation mediated by high affinity ligands increase HDL level and induces 
cholesterol efflux (9). LXRs also play a role in lipogenesis and triglyceride synthesis primarily due to 
the upregulation of sterol regulatory element binding protein-1c (SREBP-1c) and fatty acid 
synthase (FAS) (10). All these genes are regulated by LXRs in a direct fashion due to the presence 
of one or multiple LXRE in the promoter region of the target genes. 
The literature on LXRs during the last two decades is mainly focused on the role of these 
nuclear receptors in the liver, adipose tissue, pancreas and skeletal muscle. During the last ten 
years several evidences have addressed the fundamental role of LXRs also in the nervous systems. 
Thus, the aim of this review is to summarize the current knowledge on LXRs in the brain, spinal 
cord and peripheral nerves. 
 
LXRs AND CHOLESTEROL METABOLISM IN THE CENTRAL NERVOUS SYSTEM 
Cholesterol is transported in the circulation by lipoproteins that are not able to cross the 
blood brain barrier. Consequently, the brain cholesterol is synthesized in situ by the central 
nervous system (CNS), mainly by neurons and glial cells (11, 12). Therefore, the brain is 
characterized by a large amount of cholesterol and it represents the most cholesterol rich organ. 
In the cerebral tissue, cholesterol is necessary for both cell functions and membrane structure of 
neurons and glial cells. Similar to other tissues also in the brain, the cholesterol homeostasis is 
regulated by LXRs, whose activation induces the expression of a plethora of genes involved in 
cholesterol trafficking and efflux.  
The brain’s cholesterol is mainly present in myelin and low cholesterol levels in CNS results 
in reduced myelination in oligondedrocytes (13). Thus, the maintenance of cholesterol 
homeostasis is crucial in the CNS. On the other hand, high cholesterol levels can lead to 
detrimental effects. Therefore, the brain needs to eliminate cholesterol by generating brain 
specific metabolites such as oxysterols which are a hydroxylated form of cholesterol and hence 
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more polar and able to cross the blood brain barrier. This latter mechanism represents 50% to 
60% of the brain cholesterol efflux, while an unknown pathway, probably involving ApoE, 
eliminates the remaining 40% (12, 14).  
In the brain, cholesterol is metabolized by its conversion into 24(S)-hydroxycholesterol and 
the release of this oxysterol reflects the rate of synthesis of cholesterol in the brain (15). A 
member of the cytochrome P450 superfamily of enzymes such as the cholesterol 24-hydroxylase 
(Cyp46a1) mediates the generation of 24(S)-hydroxycholesterol. This enzyme is exclusively 
expressed in the brain and in particular in hippocampal and cortical neurons that are important for 
learning and memory formation (16). Once produced, the 24(S)-hydroxycholesterol diffuses out of 
cells, crosses the blood brain barrier, and by systemic circulation reaches the liver for its final 
clearance (15). To better understand the role of Cyp46a1 in the brain, Lund and collaborators 
generated a mouse model lacking 24-hydroxylase that exhibited reduced cholesterol excretion 
(14). These animals showed severe deficiencies in spatial, associative, and motor learning, and in 
hippocampal long-term potentiation (LTP). Indeed, the disruption of the cholesterol 24-
hydroxylase gene in the mouse leads to slower cholesterol excretion and in the suppression of the 
mevalonate pathway in the brain. The administration of geranylgeraniol to Cyp46a1 null 
hippocampal slices restored the LTP to wild type mice indicating that this molecule is essential for 
learning and that cholesterol turnover via the 24-hydroxylase enzyme is important to actively 
maintain the mevalonate pathway (16). 
The ApoE is the most abundant apolipoprotein in the CNS and it is involved in lipoprotein 
assembly and secretion under the direct control of LXRs. Astrocytes from ApoE deficient mice 
secrete a low amount of free cholesterol (17) leading to neurodegeneration during aging (18) and 
impairment in learning and memory (19). The nascent cholesterol-containing lipoproteins are 
lipidated by ABC transporters such as ABCA1, ABCG1 and ABCG4, the latter highly expressed into 
the CNS (20). The cholesterol efflux from astrocytes is mainly mediated by the action of ABCA1 
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and ABCG1, while in neurons this function is predominantly carried out by ABCG4 (21). ABCA1 
knock-out mice exhibit markedly decreased levels and lipidation of ApoE in the CNS. Thus, the 
ApoE produced in this context is resulted to be strongly amyloidogenic in vivo and favor the 
development of Alzheimer’s disease (22). Moreover, the loss of both ABCG1 and ABCG4 
expression in the brain results in oxysterols accumulation and reduced expression levels of LXRs 
and sterol regulatory element binding protein 2 (SREBP2) target genes while, ABCG4 null mice 
display a general deficit in associative fear memory (20). Although it is well established that both 
ABCA1 and ABCG1 are directly regulated by LXRs (2), the expression of ABCG4 is not affected by 
LXRs activation (23). Despite the generation of several knock-out models of the ABC transporters, 
it still seems difficult to establish which one may play a major role in mediating cholesterol efflux. 
Probably the expression of the ABC transporters in different CNS cells accounts for a differential 
efflux of cholesterol regulated in a different manner. However, this is a hypothesis that needs to 
be supported by further studies. 
Another role of LXRs in controlling cholesterol uptake is the regulation of inducible 
degrader of LDL receptor (IDOL). IDOL is an E3 ubiquitin ligase that favors the degradation of the 
LDL receptor (LDLR) (24). IDOL is expressed in neurons and it has been suggested to inhibit neurite 
outgrowth (25). Moreover, Hong and collegues extended these observations by demonstrating 
that IDOL modulates the levels of the VLDL receptor (VLDLR) and of the apolipoprotein E receptor 
2 (ApoER2 or known also as LDL receptor-related protein 8, LRP8), through a mechanism involving 
receptors ubiquitination, leading to reduced reelin binding. These data suggest that IDOL, through 
LXR activation, may have a role during neurons development (26).  
In conclusion, cholesterol is synthesized directly in the brain and an abnormal 
accumulation of cholesterol may result in neurodegeneration and favor the onset of cholesterol-
associated nervous system disorders. Thus, the main role of LXRs in the brain is to promote 
cholesterol efflux to maintain cholesterol homeostasis in this tissue. 
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LXRs AND NEURODEGENERATIVE DISEASES 
In the CNS both LXRα and LXRβ isoforms are expressed, however, LXRβ is the most 
abundant isotype in the central nervous system (27). 
The generation of LXRs knock-out mice and the development of different synthetic 
compounds shed the light on the physiology and the functions regulated by these transcription 
factors. Indeed, double LXR knock-out (LXRDKO) mice exhibit numerous severe abnormalities such 
as loss of neurons, proliferation of astrocytes, disorganization in myelin sheaths, accumulation of 
lipid deposits and closure of ventricules (28) in the CNS. 
On this ground, we will examine the roles of LXRs in neurodegenerative diseases as also 
summarized in figure 1. 
  Alzheimer’s disease. Cholesterol accumulation in the CNS increases the risk of developing 
Alzheimer’s disease (AD) (29). AD is characterized by progressive neuronal degeneration, gliosis, 
extraneuronal deposition of amyloid-β peptides (Aβ) forming senile plaques and intraneuronal 
accumulation of hyperphosphorylated tau protein (neurofibrillary tangles) (30, 31). The lack of 
either LXRα or LXRβ in APP23 transgenic mice (a mouse model of AD) causes an increased amyloid 
deposition (32). AD is also characterized by microglial activation and neuroinflammatory 
processes. In this regard, LXRs activation by synthetic agonists decreased the inflammatory 
response of primary mixed glial cultures to fibrillar amyloid β peptide (fAβ). On the other hand, 
cells lacking LXRs displayed a higher expression of inflammatory genes suggesting that LXRs may 
act as endogenous inhibitors of the innate CNS response induced by fAβ (32). The anti-
inflammatory properties of LXRs agonists on a mouse model of AD may be due, at least in part, to 
inhibition of NF-κB signaling pathway (33). Fitz and collegues reported that a high fat diet 
exacerbated the AD phenotype. In this context, the authors demonstrated that LXRs activation by 
reducing amyloid load and facilitating its clearance improves AD phenotype (34). Another protein 
that is considered associated with the development of AD is selective Alzheimer's disease 
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indicator-1 (Seladin 1) (35). This protein catalyzes the conversion of desmosterol into cholesterol 
and therefore is also known as 3-β-hydroxysterol delta-24-reductase (Dhcr24) (35). During the 
onset of AD, seladin is downregulted, thus favoring the production of β-amyloid. Moreover, it has 
been demonstrated that the overexpression of Seladin 1 had protective effects by increasing the 
cholesterol content of the membrane and conferring resistance against β-amyloid aggregates in 
neuroblastoma cells. On the other hand, the specific inhibition of this enzyme increased cell 
susceptibility (36). In addition, a whole genome screen for the identification of novel direct LXR 
target genes, an LXRE, was detected in the second intron of Seladin 1 gene (37). This is another 
potential mechanism by which LXR activation protects against AD. However, to test the hypothesis 
that LXR activation requires Seladin 1 to exert protective effects on AD, further studies need to be 
performed in Seladin 1 knock-out mice that have an altered membrane composition due to brain 
cholesterol deficiency. Finally, all these studies suggested that LXRs activation might be a useful 
tool for the treatment of AD. 
Parkinson’s disease. Microgliosis, astrogliosis, progressive degeneration of dopaminergic 
neurons, presence of Lewy bodies in dopaminergic neurons, and α-synuclein accumulation in 
substantia nigra pars compacta defines Parkinsons’s disease (PD) (38). Male LXRβ knock-out mice 
show an adult-onset motor neuron degeneration after 7 months of age (39) and the LXRβ 
deficiency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD, 
exacerbates the already affected dopaminergic neuron condition (40). LXRs activation in MPTP 
treated wild type mice protected against the MPTP-induced neurodegeneration of dopaminergic 
neurons and reduced glial cells activation (40). Since LXRβ was not found to be expressed in 
dopaminergic neurons, the authors concluded that LXR activation exerts the protective effects in 
PD by acting on the cytotoxic functions of microglia (40). 
Hungtington’s Disease. This pathology is characterized by abnormal expansion of the 
polyglutamine tract located in the N-terminus of an ubiquitous expressed protein known as 
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huntingtin. It was demonstrated that the cholesterol biosynthetic pathway is altered in HD mice 
brains and postmortem human striatal and cortical tissues (41). Recently, it was reported that wild 
type huntingtin activates LXRs mediated transcription and thus unravels a new LXRs coactivator. 
Furthermore, the overexpression of mutant huntingtin has negative effects on LXRs target genes 
such as ABCA1, an effect partially rescued by LXR activation by a synthetic ligand (42). These data 
propose a role of LXR in the pathophysiology of HD probably involving cholesterol homeostasis. 
However, more work needs to be done to ascertain the role of LXRs in HD. 
Multiple Sclerosis. This is an inflammatory disease characterized by demyelination in CNS 
due to extensive damages of the myelin around the axons. Since LXRs have potent anti-
inflammatory activities (43), recent studies have demonstrated the efficacy of LXRs agonists in the 
treatment of multiple sclerosis (MS). It is known that Th1 and Th17 cells contribute to the 
development of autoimmune diseases among with MS (44, 45). An established animal model of 
MS is the experimental autoimmune encephalomyelitis (EAE), an inflammatory disease of the 
central nervous system characterized by demyelination, with a histopathology similar to the 
human disease (46, 47). It has been reported that the LXRs agonist T0901317 blocked the 
production of nitric oxide and inhibited the induction of proinflammatory cytokines and 
chemokines by LPS-stimulated primary mouse astrocytes and microglia (48). A more recent study 
also showed that T0901317 suppressed IL-23 and IL-17 expression in primary glial cells and in 
splenocytes from EAE mice (49). Moreover, administration of this LXRs agonist prior to the onset 
of the disease blocked the development of EAE through suppression of T-cell proliferation and 
cytokines release (50). Only recently Cui and colleagues (51) performed experiments in wild type 
mice and in LXRDKO with two different LXRs synthetic ligands, GW3965 and T0901317, since 
T0901317 cross-reacts also with other nuclear receptors such as the bile acids receptor FXR and 
the xenobiotic receptor PXR (52). They demonstrated that both ligands ameliorated EAE in wild 
type mice but not in LXRDKO mice, indicating that the beneficial effects showed are due to LXRs 
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activation. The positive effects exerted by LXRs activation are mediated by the induction of the 
LXRs target genes SREBP-1, which mediated the suppression of Th17 by binding to the IL-17 
promoter (51). Collectively, these studies suggest that the LXRs ligands may be useful therapeutics 
for treatment of MS.  
Niemann-Pick type C1. The Niemann-Pick type C1 (NPC1) protein is a fundamental 
molecule for the intracellular trafficking of cholesterol, favoring the shuttling of LDL to lysosome to 
hydrolized and released free cholesterol. The disease is characterized by a mutation in the NPC1 
protein that results in the accumulation of unesterified cholesterol, sphingomyelin and glycolipids 
into the lysosomes of neurons and glia cells. Accumulation of these lipids in the CNS leads to 
ataxia, dysarthria, dysphagia, and in severe cases can also cause dementia and epileptic seizures 
(53). Given the large accumulation of cholesterol into the cells, treatments favoring cholesterol 
efflux may improve the Niemann-Pick type C1 disease. In this regard, Repa and collegues 
demonstrated that LXR activation in a mouse model of NPC1 disease increased cholesterol 
excretion from the brain, blunted inflammation, slackened neurodegeneration, and ultimately 
extended lifespan and improved the NPC1 phenotype (54). Moreover, cholesterol removal 
mediated by 2-hydroxypropyl-β-cyclodextrin in NPC1 knock-out mice blocked cholesterol 
biosynthesis by inhibiting the action of SREBP2 and activated LXR target genes. In addition, 
constant administration of cyclodextrin avoided the neurodegeneration observed in NPC1 knock-
out mice. These results demonstrated that cyclodextrin treatment restored cholesterol trafficking 
from lysosomes to cytosol, thus such cholesterol disposal compound may be useful for the 
treatment of the NPC1 disease (55).  
Stroke. Anti-inflammatory strategies can be a useful tool also for the treatment of ischemic 
injury. In this field, two independent studies demonstrated the protective role of LXRs activation 
on brain ischemia. The first study reported that a single dose of GW3965, delivered 2 hours post-
injury, ameliorates the extent of cytotoxic edema that result from ischemic insult. The authors 
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demonstrated that LXR activation leads to reduced neuroinflammation and to the promotion of 
vascular endothelial grow factor (VEGF) expression, another protective agent in brain ischemia 
(56). The second study confirmed the neuroprotective properties of LXRs activation in the 
experimental model of stroke and provided evidences that the lack of LXRs had detrimental 
effects on the infarct volume in an animal model of stroke (57). Another study reported similar 
results described above and provided a potential mechanism whereby LXRs activation reduced NF-
κB activation, which led to a decrease in cyclo-oxygenase-2 (COX-2) expression and finally 
ameliorated brain inflammation (58). All these data highlight that activation of the LXRs exerts a 
neuroprotective effect in the experimental model of stroke.  
Amyotrophic lateral sclerosis. A study performed in male LXRβ null mice showed that these 
animals presented motor neuron degeneration related with lipid accumulation in the spinal cord 
(39). Chronic motor neuron degeneration is associated with amyotrophic lateral sclerosis (ALS). 
The main feature that spinal cords of ALS patients have in common is a pathological accumulation 
of sphingomyelin, ceramides, and cholesterol esters (59). These lipid classes seem to be 
responsible for motor neuron sensitization for programmed cell death. Moreover, it has been 
demonstrated that in LXRβ knock-out mice, motor dysfunction progresses with age and finishes 
with paralysis (39). The authors reported that the onset of disability occurs in mice lacking LXRβ 
between 3 and 7 months of age. At 7 months of age those knock-out animals showed a reduced 
control of muscle action and problems with motor coordination associated with lipid accumulation 
(39). Because LXRβ null mice displayed motor neuron phenotype the same team investigated the 
toxicity of a known motor neuron toxin such as β-sitosterol. In this study, the administration to 8-
month-old LXRβ null mice of β-sitosterol induced motor neuron death in the lumbar region of the 
spinal cord. Moreover, in 16-month-old LXRβ knock-out mice, β-sitosterol caused severe paralysis 
and symptoms correlated with dopaminergic dysfunctions leading to an ALS phenotype. A possible 
explanation of this phenotype is that the lack of LXRβ leads to high cholesterol efflux from the 
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brain through 24-hydroxycholesterol and neuronal toxicity probably due to the LXRα activation by 
β-sitosterol (60). In conclusion, the correct balance of cholesterol in the brain is fundamental for 
the functionality of this organ and because LXRs play a part in the regulation of cholesterol 
homeostasis, it can be a useful target for the treatment of the neurodegenerative disease 
associated with defects in this pathway. However, a long-lasting activation of LXRs may result in 
detrimental effects on the brain such as neurotoxicity. 
Glioblastoma. Glioblastoma (GBM) is the most common and malignant primary brain 
tumor and among different kind of cancer it is one with a poor prognosis. Guo and collegues have 
recently elucidated the role of cholesterol homeostasis in this lethal tumor (61). Indeed, they 
provide evidences of increased cholesterol uptake in the GBM due to the mutated epidermal 
growth factor receptor (EGFR) activated pathway involving phosphoinositide 3-kinase (PI3K) and 
SREBP-1 leading to up-regulation of the LDL receptor (LDLR) (61). Moreover, LXRs activation 
promoted LDLR degradation by inducing its target gene IDOL and increased expression of the 
cholesterol efflux transporter ABCA1. These effects promoted cell death and inhibited tumor 
growth in vivo (58).  
Smith-Lemli-Opitz syndrome. Smith-Lemli-Opitz syndrome (SLOS) is characterized by the 
deficiency of 7-dehydrocholesterol reductase (Dhcr7). Therefore, affected subjects display the 
inability to correctly produce or synthesize cholesterol. Cholesterol supplementation after birth is 
the current approach, however, the lack of cholesterol in utero drives to developmental 
malformations. On this ground, it has been proposed that in utero treatment with a LXRs agonist 
of a model of SLOS pregnant female mice (Dhcr7 knock-out mice), incapable of de novo synthesis 
of cholesterol, increase the placental expression of ABCA1 allowing the maternal to fetus 
cholesterol transfer. These data suggest that LXRs activation may have potential for in utero 
therapy of SLOS (62).  
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ENDOCRINOLOGICAL IMPLICATIONS OF LXRs ACTIVATION IN THE CENTRAL NERVOUS SYSTEM 
Despite the synthesis of steroids in peripheral tissues (i.e. adrenal gland and gonads), CNS 
produces these hormones to regulate physiological functions in the brain and in the spinal cord. 
Thus, they are named neuroactive steroids (63, 64). Several neurodegenerative conditions (such as 
Alzheimer's disease, Parkinson's disease, Multiple Sclerosis and Charcot-Marie-Tooth type 1A) are 
associated with modified levels of neuroactive steroids (65, 66, 67, 68). In this regard our 
laboratory provided evidences that age related neuropathological changes in AD brains were 
associated with modified levels of specific neuroactive steroids such as changes in the levels of 
progesterone and testosterone metabolites (65). Moreover, another example is represented by 
the improvement of the MS phenotype in the experimental autoimmune encephalomyelitis (EAE) 
rat model by the treatment with progesterone, which blunted the neuroinflammation (67). 
The precursor of neuroactive steroids is cholesterol, thus CNS expresses all key enzymes 
for the neuroactive steroids synthesis (69). Because cholesterol is central for the neuroactive 
steroid synthesis and LXRs are cholesterol sensing transcription factors, it is possible that LXRs may 
regulate the amount of cholesterol available for the neuroactive steroids to be synthesized. 
Indeed, our laboratory evaluated whether the LXRs activation may regulate neuroactive steroid 
levels in the CNS of diabetic animals compared with non-diabetic controls. We found that diabetes 
reduced neuroactive steroid levels in different areas of the CNS. The LXRs activation selectively 
increased the levels of some neuroactive steroids and rescued the CNS symptoms due to diabetes 
(70). Our results suggest that LXRs activation also influences neuroactive steroid levels in the CNS. 
Thus, it might be possible that the neurodegenerative diseases associated with decreased levels of 
neuroactive steroids where LXRs showed protective effects may have involved also the regulation 
of the neuroactive steroid biosynthetic pathway.  
 However, more studies are necessary to prove the protective role of the LXR-neuroactive 
steroid axis in the CNS. 
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CENTRAL LXRs IN THE CONTROL OF ENERGY METABOLISM 
 Nowadays several studies demonstrated the fundamental role of the brain in the control of 
whole body energy homeostasis (71). This control is the result of hormonal signals generated by 
peripheral organs and nutrients such as glucose, free fatty acids and amino acids and of the 
consequent CNS responses to adapt the body to the nutritional status (72). The main area involved 
in the control of central energy balance is the hypothalamus. Dysregulation of hypothalamic 
functions lead to development of metabolic disorders. In fact, rodent models challenged with high 
fat diet and obese subjects developed hypothalamic inflammation and gliosis leading to neuronal 
injury and decrease number of pro-opiomelanocortin (POMC) neurons that are crucial 
components of the network controlling energy balance. These detrimental effects may be 
associated with increased body weight (73). Moreover, several studies draw the attention to the 
association between metabolic syndrome, a complex disease characterized by insulin resistance, 
dyslipidemia and elevated blood pressure, and the development of cognitive disorders including 
also Alzheimer’s disease (74).  
 Recently, Kruse and collegues reported that the paraventricular and ventromedial nuclei 
express mainly LXRα whereas the arcuate nucleus expresses LXRβ. Moreover, fructose fed rats 
selectively decreased hypothalamic LXRβ levels while LXRα increased. This work highlighted a 
possible relationship between glucose and the expression of LXRs in the hypothalamus, indicating 
a role for LXRs in the control of food intake and energy expenditure (75). In addition to the 
possibility of energy intake control it has been also demonstrated that hypothalamic LXRβ 
regulates arginine vasopressin and consequently body water balance. When this pathway is not 
properly regulated as in the LXRβ knockout mice showing reduced number of hypothalamic 
vasopressin positive neurons, these animals developed diabetes insipidus (76). Despite the role of 
LXRs in hypothalamus that still needs to be completely addressed to prove a role for these 
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receptors in the control of energy metabolism, in peripheral organs LXRs activation directly impact 
hormone levels that may affect brain such as insulin and leptin.  
The effects on insulin relies on the ability of LXRs to reduce the expression of 
gluconeogenic genes in the liver such as phosphoenolpyruvate carboxykinase (PEPCK), glucose 6-
phosphatase (G6Pase) and Peroxisome Proliferator Activated receptor γ coactivator-1 (PGC-1), 
while on the other hand induces glucokinase (GK) the first enzyme in the glycolysis pathway (77). 
Furthermore, in white adipose tissue the activation of LXRs induce the expression of the insulin-
sensitive glucose transporter-4 (GLUT-4) (77). Therefore LXRs activation reduced blood glucose 
and improved insulin sensitivity in animal models of type 2 diabetes (78). LXRs play also an 
important role in pancreatic beta cells. These cells exclusively express LXRβ (79). LXRβ knock-out 
mice do not secrete insulin in response to glucose showing an impaired glucose tolerance 
phenotype (80). To sustain a role of LXRs in beta cells it also has been demonstrated that 
T0901317, a synthetic LXR agonist, caused, in pancreatic islets and in MIN6 cells, an increase in 
glucose-dependent insulin secretion and in islet insulin content (81). Remain controversial the role 
of LXRs agonists in the stimulation of insulin secretion, some studies showed an increased in 
plasma insulin concentration (82, 83) while others report no significant effects (84, 85, 86). In 
pancreatic beta cells the glucose and lipid metabolism appears responsible for the insulin 
secretion induced by LXRs agonists. In this view seems important the upregulation of the lipogenic 
LXRs target genes such as SREBP-1c, FAS and ACC which regulate the fatty acids and malonyl Co-A 
synthesis that ultimately stimulate insulin production and secretion (79). On the other hand a 
prolonged exposure to the synthetic LXRs ligand T0901317 has been associated with lipotoxicity 
due to triglycerides and free fatty acids accumulation in pancreatic islets (86). In addition, the 
activation of LXRs with synthetic ligands induces hypertriglyceridemia. These effects worsened 
when the db/db diabetic mouse models were treated for 12 days with T0901317. These animals 
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showed increased liver mass and severe hepatic steatosis along with reduced blood glucose and 
PEPCK expression (87). On this ground the antidiabetic potential of LXRs ligands has been limited. 
Leptin is a hormone controlling nutritional status of the body and defects in its function 
leads to obesity (88). It has been reported that leptin is directly regulated by LXRs indicating a 
connection with the nutritional status. Indeed, mice fed with the LXRs agonist T0901317 resulted 
in a two-fold downregulation of leptin expression in white adipose tissue (89). These data suggest 
that LXRs agonist may increase food intake by blunting leptin expression an undesired effects in 
terms of obesity development. Taken together these data indicate a potential role of LXRs in the 
brain in the regulation of energy metabolism, however more careful investigations are necessary 
to better elucidate the role of LXRs in hypothalamus. Moreover, new ligands discerning between 
lowering glucose levels and inducing lipogenesis may be useful for the treatment of metabolic 
disorders associated to altered energy homeostasis.  
 
LXRs AND CHOLESTEROL METABOLISM IN PERIPHERAL NERVOUS SYSTEM 
The peripheral nervous system (PNS) consists of nerves and ganglia and different from the 
CNS is much more exposed to injuries due to the lack of blood brain barrier and/or bones.  
Peripheral neuropathies are common disorders affecting PNS. Peripheral neuropathies may 
arise during the aging process, after mechanical injury, by metabolic disorders (e.g., diabetes 
mellitus), by infections and autoimmune diseases, or after exposure to such type of therapeutics 
or toxic compounds. Damages to the PNS can also be inherited as in the case of the Charcot–
Marie–Tooth (CMT) disease (63).  
As previously described in the CNS, in the PNS also cholesterol plays a crucial role. Similarly 
to the CNS, in the PNS the majority of cholesterol is found in myelin and in particular in peripheral 
myelin producing cells such as the Schwann cells. To investigate the role of cholesterol in Schwann 
cells, two different mouse models have been generated and characterized. The first is a mouse 
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model where the squalene synthase, a key enzyme to produce cholesterol, has been inactivated 
(SQS mice). The second model is a Schwann cells specific knock-out of the SREBP cleavage 
activation protein (SCAP). The SREBPs are a family of transcription factors regulating genes in 
cholesterol and fatty acid biosynthesis, the major components of the myelin sheath. Both models 
developed peripheral neuropathy due to a reduced myelination of the sciatic nerve. Moreover, in 
the SQS mutant Schwann cells it has been demonstrated that the export from the endoplasmic 
reticulum of the major myelin protein P0 to growing myelin is dependent on cholesterol. These 
data undoubtedly prove the important role of cholesterol and fatty acids in myelin generation (13, 
90). Given the key role of lipids in the PNS and that LXRs are central in the regulation of 
cholesterol homeostasis and fatty acid metabolism, it is important to address their biology in this 
tissue either in physiological or in pathological conditions. In this regard, our laboratory 
demonstrated that both LXR isoforms are expressed and functional in the sciatic nerve (91). 
Makoukji and colleagues highlighted the importance of LXRs in regulating myelin peripheral 
nerves. Indeed, this team demonstrated that LXRDKO mice displayed thinner myelin compared 
with the age matched in wild type control animals (5). Thus, the lack of LXRs in the sciatic nerve 
alters the myelin structure (5).  
From an endocrinological point of view, extensive literature reported the vital role of 
neuroactive steroids in PNS. As described in the CNS, the PNS also expresses the genetic makeup 
for the biosynthesis of neuroactive steroids. On this ground, several studies showed that 
neuroactive steroids are protective agents on peripheral neuropathy (63, 64, 69). Given that 
neuroactive steroids are cholesterol-derived molecules, we hypothesized that LXRs may have 
protective effects on peripheral neuropathy by modulating the levels of these hormones. Thus, we 
investigated the effects of LXRs activation in the contest of peripheral neuropathy induced by a 
metabolic disorder such as diabetes. In this contest, as previously reported by other studies, we 
showed that diabetes decreased the neuroactive steroid levels in the sciatic nerve. However, upon 
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LXRs activation by a synthetic ligand, the levels of some neuroactive steroids were restored to the 
levels detected in non-diabetic animals (91). The molecular mechanism involved the induction of a 
classical LXRs target gene such as the sterol acute regulatory protein (StAR) (8, 91). In fact, this 
protein is a cholesterol transporter that favored the cholesterol shuttling into mitochondria. Once 
in this organelle, cholesterol is the substrate of the cytochrome P450 side chain cleavage (P450scc 
or Cyp11a1) that generates pregnenolone, the first steroid in the biosynthetic pathway (91). From 
this study we concluded that LXRs activation promoted cholesterol utilization within the sciatic 
nerve. Similar results were also obtained in another study by using a synthetic activator of the 
translocator protein 18 kDa (TSPO). Similar to StAR, the main function of this protein is to 
transport cholesterol into the mitochondria which is a required step for the steroidogenesis (92). 
Moreover, Verheijen and colleagues, by using the SCAP Schwann cells-specific knock-out 
demonstrated that not only cholesterol is important for myelin formation but also fatty acids (90). 
One of the lipogenic regulators is represented by SREBP-1c, a transcription factor under the direct 
control of LXRs. Our laboratory provided evidences that diabetic peripheral neuropathy is 
characterized by myelin abnormalities due to an altered myelin cholesterol and fatty acid profile 
(93). LXRs activation in the contest of diabetes restored myelin lipids to those found in the myelin 
of control animal peripheral nerves. These effects were mediated by a restored nuclear 
localization of SREBP-1c, after the LXRs activation, which was blunted by diabetes. Along with a 
restored lipid profile, LXRs also restored the levels of the myelin protein P0 (93). The positive 
effects of LXRs activation on diabetic peripheral neuropathy were associated with improved 
functional tests as an outcome to score the pathology (93). The roles of LXRs in the PNS are 
summarized in figure 2. 
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CONCLUSIONS 
Lipid homeostasis is crucial to maintain the physiological function of the central nervous 
system and the peripheral nervous system. Diseases affecting both cholesterol and/or fatty acid 
metabolism have negative effects either in the CNS and/or in the PNS. Several evidences based on 
mice lacking LXRs in the nervous system indicated the critical role of this transcription factor in 
preserving a healthy phenotype, thus highlighting its importance in both the CNS and the PNS. 
Interestingly, it is of outmost importance that the activation of LXRs in neurodegenerative 
diseases, generally, had protective effects. Most of the beneficial effects of LXRs activation in 
neurodegenerative diseases have been ascribed to its ability to blunt the inflammatory response. 
However, LXRs also modulate the levels of neuroactive steroids. These molecules have been 
extensively studied for their beneficial effects on neurodegenerative diseases. However, their 
therapeutic potential has been limited by their systemic side effects. The LXRs ligand may by-pass 
these side effects of the hormones because they activate locally, in the nervous system, the 
steroidogenesis that ultimately confers neuroprotection. On the other hand, LXRs activation may 
leads to hypertriglyceridemia and liver steatosis.  
In conclusion, LXRs may represent an attractive target for the treatment of 
neurodegenerative diseases in the CNS and/or the PNS. However, the discovery of new ligands 
and/or trials with different protocols of drug administration may result in maintaining the LXRs 
beneficial effects and avoiding those adverse. 
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LEGEND TO FIGURES 
Figure 1. Role of LXRs in the central nervous system. Green arrows and red symbols represent the 
induced and the repressed genes and pathways after LXRs activation, respectively.  
Liver X Receptors (LXR), ATP binding cassette A1 (ABCA1), ATP binding cassette G1 (ABCG1), 
Apolipoprotein E (Apo E), Low Density Lipoprotein Receptor (LDLR), Inducible Degrader of the 
LDLR (IDOL), Very Low Density Lipoprotein Receptor (VLDLR), Apolipoprotein E Receptor 2 
(ApoER2), Sterol Regulatory Element Binding Protein-1c (SREBP-1c), Interleukin-17 (IL-17), 
selective Alzheimer's disease indicator-1 (Seladin 1)/3-β-hydroxysterol delta-24-reductase 
(Dhcr24), Smith-Lemli-Opitz syndrome (SLOS). 
 
Figure 2. Role of LXRs in the peripheral nervous system. Green arrows represent the induced and 
genes and pathways after LXRs activation.  
Liver X Receptors (LXR), Cholesterol (Chol), Sterol Acute Regulatory Protein (StAR), Translocator 
Protein 18 kDa (TSPO), Cytochrome P450 side chain cleavage (P450scc), Pregnenolone (PREG), 
Sterol Regulatory Element Binding Protein-1c (SREBP-1c). 
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